KKR has pulled out of a private equity consortium that was exploring a takeover of Gerresheimer AG, according to a Bloomberg report citing sources familiar with the situation. Warburg Pincus, another member of the consortium, is still pursuing a potential deal.

Earlier this month, it was reported that the consortium, which included KKR and Warburg Pincus, had made a non-binding bid for Gerresheimer. The company, known for manufacturing pens used in weight-loss drug injections like Novo Nordisk’s Wegovy, has a market capitalization of approximately 2.22 billion euros.

The consortium's bid was around 90 euros per share, valuing Gerresheimer at nearly 3.1 billion euros, or about $3.42 billion. Both Gerresheimer and Warburg Pincus declined to comment on the situation, while KKR did not respond to requests for comment.

In February, Gerresheimer indicated it was in preliminary discussions with private equity investors regarding a potential sale, noting that the interest was informal and non-binding.